David Tadin, MD
Interventional Cardiology · Lafayette, LANPI 1508131814
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.5% of the total across 330 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 14.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $3,212 and has fallen 54.8% since, to $1,450 in 2025.
Across 330 payments — averaging $33.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abiomed$2K
- Penumbra, Inc.$1K
- Boston Scientific$798
- Novartis$732
- Cardiovascular Systems Inc.$650
- Angiodynamics, Inc.$649
- plus $5K from 33 others
What the payments were for
- Travel & lodging$1,0139%
- Food & beverage$9,96791%
- Education$280%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abiomed | 37 | $1,554 |
| Penumbra, Inc. | 6 | $1,364 |
| Boston Scientific | 12 | $798 |
| Novartis | 44 | $732 |
| Cardiovascular Systems Inc. | 13 | $650 |
| Angiodynamics, Inc. | 15 | $649 |
| E.r. Squibb & Sons, L.L.C. | 37 | $647 |
| Shockwave Medical, Inc | 31 | $559 |
| Medtronic(2 entities) | 8 | $552 |
| Pfizer | 21 | $437 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 25 | $334 |
| Johnson & Johnson | 17 | $330 |
| Boehringer Ingelheim | 5 | $286 |
| Philips North America LLC | 7 | $284 |
| Novo Nordisk | 5 | $183 |
| Edwards Lifesciences | 2 | $179 |
| CSL Behring | 1 | $170 |
| Inari Medical, Inc. | 1 | $163 |
| Silk Road Medical, Inc. | 1 | $150 |
| Surmodics, Inc. | 1 | $145 |
| Amgen | 4 | $124 |
| Abbott | 6 | $117 |
| Alnylam Pharmaceuticals Inc. | 4 | $105 |
| Atricure, Inc. | 4 | $95 |
| Merck | 5 | $82 |
| AstraZeneca | 3 | $42 |
| Regeneron Healthcare Solutions, Inc. | 2 | $40 |
| Cardiva Medical, Inc. | 2 | $38 |
| Impulse Dynamics (USA) Inc. | 1 | $29 |
| Cvrx, Inc. | 1 | $25 |
| Endologix LLC | 1 | $24 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $22 |
| Astellas Pharma US Inc | 1 | $21 |
| Arbor Pharmaceuticals, Inc. | 1 | $16 |
| Scpharmaceuticals Inc. | 1 | $16 |
| Mannkind Corporation | 1 | $16 |
| Kestra Medical Technology Services, Inc. | 1 | $16 |
| Cordis US CORP. | 1 | $13 |
| Asahi Intecc USA, Inc. | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Indigo System$1,265
- Impella$656
- Resolute$476
- Diamondback Peripheral$360
- JARDIANCE$234
- Ranger$207
- FlowTriever$163
- ClotTriever$163
- ENROUTE Transcarotid Neuroprotection System$150
- ENROUTE Transcarotid Stent$150
- Sublime 014 Rx PTA Balloon Dilatation Catheter$145
- Sublime Radial Access 018 RX PTA Dilatation Catheter$145
- Sublime Radial Access Guide Sheath$145
- Pounce Thrombectomy System$145
- Pounce Venous Thrombectomy System$145
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$131
- Ozempic$120
- (6391) Nexcimer$111
- SYNERGY$111
- VYNDAQEL$109
How this compares
$11,008 in reported general payments places this provider in the 55th percentile of 171 interventional cardiology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 431 | $367,160 |
| EntrestoSacubitril/Valsartan | 257 | $231,311 |
| CamzyosMavacamten | 24 | $188,126 |
| XareltoRivaroxaban | 227 | $167,489 |
| Repatha SureclickEvolocumab | 83 | $53,483 |
| JardianceEmpagliflozin | 53 | $53,343 |
| Praluent PenAlirocumab | 29 | $22,436 |
| FarxigaDapagliflozin Propanediol | 23 | $21,486 |
| VascepaIcosapent Ethyl | 24 | $14,033 |
| NexlizetBempedoic Acid/Ezetimibe | 25 | $10,587 |
| Metoprolol Succinate | 580 | $6,626 |
| Atorvastatin Calcium | 793 | $6,040 |
| Amiodarone Hcl | 120 | $4,254 |
| Rosuvastatin Calcium | 384 | $4,088 |
| Omega-3 Acid Ethyl Esters | 45 | $3,007 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $437 | $367,160431 claims |
| NovartisEntresto | $732 | $231,311257 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $647 | $188,12624 claims |
| Johnson & JohnsonXarelto | $330 | $167,489227 claims |
| Boehringer IngelheimJardiance | $286 | $53,34353 claims |
| AstraZenecaFarxiga | $42 | $21,48623 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 171 interventional cardiology providers in Louisiana.
Other interventional cardiology in Lafayette
- Ankur LodhaLafayette$640K
- Agostino IngraldiLafayette$315K
- Louis SalvaggioLafayette$214K
- Eric ThomasseeLafayette$149K
- Amit AminLafayette$82K
- Raghotham PatlolaLafayette$76K
- Craig WalkerHouma$5M
- Denzil MoraesBaton Rouge$901K
- Rajan PatelNew Orleans$517K
- Steven BaileyShreveport$305K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.